Agios signs $165M deal for blood disorder drug from Korea’s Oscotec that flunked phase 2 study

Days after its lead clinical-stage asset suffered a setback, Agios Pharmaceuticals has rebounded by buying a blood disorder drug that flunked a phase 2 study.